NEW YORK, United States, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026” in its research database.
“According to the latest research study, the demand of global Irritable Bowel Syndrome (IBS) Diagnostics Market size & share was valued at approximately USD 1.2 Billion in 2020 and is expected to reach a value of around USD 2.3 Billion by 2026, at a compound annual growth rate (CAGR) of about 9.7% during the forecast period 2021 to 2026.”
What is Irritable Bowel Syndrome (IBS) Diagnostics? How big is the Irritable Bowel Syndrome (IBS) Diagnostics Market?
- Market Overview & Coverage:
Irritable bowel syndrome is a medical condition that pertains to irregular bowel movement and is accompanied by extreme pain in the stomach followed by diarrhoea, cramping, and constipation among others. IBS is a fairly simple diagnosis that can be detected by a range of laboratory tests and imaging tests with a wider range of medication as treatment measures. The driving factors behind the growth of the irritable bowel syndrome (IBS) diagnostics market are a rise of prevalence of factors such as food allergies, predominant development of gastroenteritis, sporadic movements of the colon, irregular composition of serotonin in the colon, and a rise in celiac diseases, among others.
Additional factors include improvement in testing methods and extensive research and developmental means for improved accuracy and less downtime during testing. Moreover, the approval of linzess among regions of the U.S, Europe, and Asia-Pacific is expected to propel the growth of the IBS diagnostic market over the forecast period. Increased awareness among consumers and a widened spending power coupled with established healthcare facilities will further lead the market toward a positive outlook.
Get a Free Sample PDF of this Research Report for more Insights with Table of Content, Research Methodology, and Graphs - https://www.fnfresearch.com/sample/irritable-bowel-syndrome-diagnostics-market
Market Dynamics:
The global irritable bowel syndrome diagnostics market is heavily driven by factors governing a higher prevalence of targeted diseases coupled with increased uptake of drugs during the forecast. Additional factors include a rise in the commercialization of existing product lines spread across various regions will further propel the growth of the market. Increased approval of linzess on a global scale will open new opportunities for the market to recoup revenue and improve sales. Improved testing methods and reliable treatment measures will further drive market growth. Moreover, an advent increase in factors pertaining to increased food allergies, predominant development of gastroenteritis, sporadic movements of the colon, the irregular composition of serotonin in the colon, and a rise in celiac diseases among the aging and advanced population will further boost the demand for IBS diagnostics over the projected forecast.
Increased awareness among consumers and manufacturers alike is expected to boost the growth of the irritable bowel syndrome (IBS) diagnostics market towards a large footprint. Collaborative efforts of global and local organizations are proving to be highly fruitful for a larger group of consumers to be made aware of IBS. An increased number of approved products from regulatory bodies across the globe open new market avenues for the IBS diagnostics market to flourish. However, lack of proper knowledge among consumers and unconfirmed diagnosis prescribed by similar practitioners is expected to constrain the growth of the market to a certain extent.
Industry Major Market Players
- Allergan
- Astellas Pharma Inc.
- Takeda Pharmaceuticals Company Limited
- AstraZeneca
- Sebela Pharmaceuticals Inc.
- Synergy Pharmaceuticals
- Banusch Health
- Synthetic Biologics Inc.
- Ardelyx
- Johnson & Johnson
- Novartis AG
Key questions answered in this report:
- What is the market size and growth rate forecast for Irritable Bowel Syndrome (IBS) Diagnostics?
- What are the main driving factors propelling the Irritable Bowel Syndrome (IBS) Diagnostics Market forward?
- What are the leading companies in the Irritable Bowel Syndrome (IBS) Diagnostics Industry?
- What segments does the Irritable Bowel Syndrome (IBS) Diagnostics Market cover?
- How can I receive a free copy of the Irritable Bowel Syndrome (IBS) Diagnostics Market sample report and company profiles?
Key Offerings:
- Market Size & Forecast by Revenue | 2021−2026
- Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
- Market Segmentation – A detailed analysis by Type, by Product, by Distribution Channel, and by Region
- Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/irritable-bowel-syndrome-diagnostics-market
Report Scope
| Report Attribute | Details |
| Market Size in 2020 | USD 1.2 Billion |
| Projected Market Size in 2026 | USD 2.3 Billion |
| CAGR Growth Rate | 9.7% CAGR |
| Base Year | 2020 |
| Forecast Years | 2021-2026 |
| Key Market Players | Allergan, Astellas Pharma, Inc., Takeda Pharmaceuticals Company Limited, AstraZeneca, Sebela Pharmaceuticals, Inc., Synergy Pharmaceuticals, Banusch Health, Synthetic Biologics, Inc., Ardelyx, Johnson & Johnson, and Novartis AG, among others |
| Key Segment | By Type, By Product, By Distribution Channel, and By Region |
| Major Regions Covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
| Purchase Options | Request customized purchase options to meet your research needs. Explore purchase options |
Segmentation Analysis
The global irritable bowel syndrome (IBS) diagnostic market can be segmented into type, product, distribution channel, and regions.
- Cholera-predominant segment is expected to witness the largest market share during the forecast period
On the basis of type, the global irritable bowel syndrome (IBS) diagnostics market can be divided into ISB-C, ISB-D, and Mixed IBS. The IBS-C can be further broken down into linzess/constella, amitiza, and others and the IBS-D can be broken down into xifaxan, viberzi, and others. The IBS-C segment is expected to dominate owing to various contributing factors such as a surge of uptake of drugs such as linzess/constella & amitiza.
On the basis of product, the global irritable bowel syndrome (IBS) diagnostics market can be broken down into rifaximin, eluxadoline, Lubiprostone, linaclotide, and others. The segment pertaining to rifaximin will account for the largest market share during the advent of the forecast owing to factors such as the rise in the geriatric population, increased consumer spending, reliable diagnosis, and advancements in technology.
Request for Customization on this Report as per your requirements - https://www.fnfresearch.com/customization/irritable-bowel-syndrome-diagnostics-market
Regional Analysis
- North America Will Lead The Market Over The Forecast In Terms Of Revenue
North America is expected to recoup the largest market share during the forecast in terms of global revenue collection followed by Europe and Asia-Pacific. The market growth in North America is primarily due to the well-established healthcare facilities, government incentives, and presence of key players in the region. Moreover, rising patient awareness and increased consumer spending power for diagnostics tests will propel the growth of the irritable bowel syndrome (IBS) diagnostics market during the forecast period.
Browse the full “Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026” Report at https://www.fnfresearch.com/irritable-bowel-syndrome-diagnostics-market
The global irritable bowel syndrome (IBS) diagnostics market can be segmented into:
By Type Segment Analysis:
- ISB-C
- Linzess/Constella
- Amitiza
- Others
- ISB-D
- Xifaxan
- Viberzi
- Others
- Mixed IBS
By Product Segment Analysis:
- Rifaximin
- Eluxadoline
- Lubiprostone
- Linaclotide
- Others
By Distribution Channel Segment Analysis
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Regional Segment Analysis:
- North America
- The U.S.
- Canada
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- The Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
Key Insights from Primary Research
- As per the analysis, the Irritable Bowel Syndrome (IBS) Diagnostics market is projected to grow yearly at a CAGR of around 9.7%.
- Through the primary research, it was stated that the Irritable Bowel Syndrome (IBS) Diagnostics market was valued at approximately USD 1.2 Billion in 2020 & will surpass a value of USD 2.3 Billion by 2026.
- On the basis of region, the “North America” region will lead the market during the forecast timeframe (2021-2026).
Request Your Free Sample Report of the Global Irritable Bowel Syndrome (IBS) Diagnostics Market @ https://www.fnfresearch.com/sample/irritable-bowel-syndrome-diagnostics-market
Browse Other Related Research Reports from Facts & Factors
- Dietary Supplements Market: https://www.fnfresearch.com/dietary-supplements-market
- Prebiotics Ingredients Market: https://www.fnfresearch.com/prebiotics-ingredients-market
- Dental Insurance Market: https://www.fnfresearch.com/dental-insurance-market
- Blood and Blood Components Market: https://www.fnfresearch.com/blood-and-blood-components-market
- Dental Periodontics Market: https://www.fnfresearch.com/dental-periodontics-market-report
- Skin and Wound Disinfection Market: https://www.fnfresearch.com/skin-and-wound-disinfection-market-report
About Facts & Factors:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.
Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Follow Us on LinkedIn: https://www.linkedin.com/company/fnfresearch
Follow Us on Twitter: https://twitter.com/fnfresearch
Follow Us on Facebook: https://www.facebook.com/factsandfactors/
Contact Us:
Sanu Thomas
USA: +1 347 690-0211
United Kingdom: +44 2032 894158
Japan: +81 50 5806 9039
India: +91 96043 17127
Email: sales@fnfresearch.com
Web: https://www.fnfresearch.com
Blog: https://dailyconsumerreports.com/
